Total expenses rose 5.01% to Rs 632.7 crore in Q4 FY24 over Q4 FY23. Cost of materials consumed was Rs 127.6 crore (up 12.78% YoY) while employee benefits expense stood at Rs 142.5 crore (up 19.85% YoY) and other expenses was Rs 285.9 crore (up 57.52% YoY) during the period under review.

For FY24, the pharmaco’s consolidated net profit surged 94.09% to Rs 1,388.3 crore on 46.78% jump in total income to Rs 4,126.9 crore over FY23.

Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India which caters to both domestic and international markets including regulated markets like United States of America and Europe.

The scrip hit 52-week high of Rs 1,108.95 in today’s intraday session.